Life Sciences

Among venture capital firms, we are unique in the way we see our portfolio companies and their technologies. Our deep technical understanding enables us to discern which biotechnology and medical device products are evolutionary or revolutionary in nature. CMEA aims to minimize risk and use capital efficiently by investing at the optimal stage. Each type of technology requires unique venture financing to reach developmental milestones and achieve success.

• Our biotechnology practice focuses on portfolio companies that engage in drug discovery and development. In the evolutionary mode, these companies use known biological pathways and consider new delivery of existing drugs. The revolutionary category involves transformational technologies and new biological pathways.



• Within the medical device area, we invest at all stages in companies with evolutionary products that have shorter R&D pathways. We also invest at mid and late stages in companies with revolutionary products that tend to have longer R&D pathways.